2026-06-14T11:55:10Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/155142025-04-04T17:02:45Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Melidou, Angeliki author Ködmön, Csaba author Nahapetyan, Karen author Kraus, Annette author Alm, Erik author Adlhoch, Cornelia author Mooks, Piers author Dave, Nishi author Carvalho, Carlos author Meslé, Margaux Mi author Daniels, Rodney author Pebody, Richard author WHO European Region author European Influenza Surveillance Network (EISN) author Pozo Sanchez, Francisco author Casas Flecha, Inmaculada author 2022-04 In the WHO European Region, COVID-19 non-pharmaceutical interventions continued slowing influenza circulation in the 2021/22 season, with reduced characterisation data. A(H3) predominated and, in some countries, co-circulated with A(H1)pdm09 and B/Victoria viruses. No B/Yamagata virus detections were confirmed. Substantial proportions of characterised circulating virus subtypes or lineages differed antigenically from their respective northern hemisphere vaccine components. Appropriate levels of influenza virus characterisations should be maintained until the season end and in future seasons, when surveillance is adapted to integrate SARS-CoV-2. Euro Surveill. 2022 Apr;27(15):2200255. 10.2807/1560-7917.ES.2022.27.15.2200255 1560-7917 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 35426364 http://hdl.handle.net/20.500.12105/15514 Europe Influenza virus Pandemic Surveillance Virus characterisation Influenza returns with a season dominated by clade 3C.2a1b.2a.2 A(H3N2) viruses, WHO European Region, 2021/22